PT-141, also known by its research designation bremelanotide, is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It is classified as a melanocortin receptor agonist and has been studied in preclinical models for its interactions with the central nervous system via hypothalamic and limbic circuitry. This article summarizes the current state of PT-141 research for informational purposes. PT-141 is strictly a research compound; it is not approved for human use outside of regulated clinical contexts and is not intended for self-administration.
Background: The Melanocortin System
The melanocortin system comprises five receptor subtypes (MC1R–MC5R) and their endogenous ligands, including α-MSH, β-MSH, and ACTH. Each receptor subtype is distributed across distinct tissue types and mediates different physiological signals in preclinical models. MC1R is primarily expressed in melanocytes; MC3R and MC4R are heavily expressed in the hypothalamus and limbic regions of the brain. PT-141 demonstrates binding affinity at MC3R and MC4R, making it a subject of interest in central nervous system and hypothalamic pathway research.
Early structure-activity relationship (SAR) work established that the cyclic structure of PT-141 confers greater proteolytic stability than the linear α-MSH peptide, a characteristic that has made it a preferred tool compound in melanocortin receptor pharmacology research (Hadley & Dorr, 2006, Peptides).
MC4R Pathway Research
The melanocortin-4 receptor (MC4R) is among the most studied GPCRs in preclinical neuroscience. Rodent and primate models have demonstrated that MC4R signaling in the paraventricular nucleus (PVN) of the hypothalamus modulates a variety of centrally-coordinated physiological responses. PT-141’s agonist activity at MC4R has made it a useful probe in this research space.
A widely cited series of studies using MC4R knockout mouse models showed that ablation of the receptor resulted in hyperphagia and altered energy balance, suggesting a role for this pathway in metabolic regulation independent of other outcomes (Huszar et al., 1997, Cell). PT-141 and related melanocortin agonists have subsequently been applied as pharmacological tools in these models to selectively re-engage MC4R signaling and study downstream cAMP and MAPK cascades.
Preclinical Behavioral Models
PT-141 has been examined in several preclinical behavioral assays. In rat and primate studies, subcutaneous or intranasal administration of melanocortin agonists including PT-141 produced measurable changes in hypothalamically-mediated behavior, findings that helped characterize the neurochemical circuit connecting MC3R/MC4R activation to behavioral output (Molinoff et al., 2003, Annals of the New York Academy of Sciences).
Research into the neuropeptide’s mechanism has suggested that its effects are centrally mediated rather than peripherally driven. Studies using blood-brain barrier crossing assessments found that bremelanotide reaches the central compartment following systemic administration, distinguishing it from some other melanocortin ligands studied in the same period (Diamond et al., 2004, Journal of Sex & Marital Therapy). This central bioavailability has made PT-141 a valued pharmacological tool in hypothalamic circuit research.
Receptor Selectivity and SAR Considerations
A key area of ongoing research interest is the selectivity profile of PT-141 across MC receptor subtypes. While PT-141 exhibits agonism at both MC3R and MC4R, the relative contribution of each receptor to observed preclinical outcomes remains an active question. SAR studies have used PT-141 as a scaffold to develop more selective analogs, including compounds with improved MC4R selectivity that reduce off-target interactions at MC3R and MC1R (Wikberg et al., 2000, Pharmacological Research).
Computational docking studies have further characterized the binding pocket geometry of MC4R, revealing that the His-Phe-Arg-Trp tetrapeptide core shared by PT-141 and native melanocortins is critical for receptor engagement. These structural insights have guided the design of second-generation melanocortin tool compounds used in receptor pharmacology research.
Cardiovascular and Blood Pressure Research
Preclinical studies have also examined hemodynamic parameters following MC receptor activation. Some rodent models using bremelanotide noted transient changes in blood pressure measurements at higher concentrations, leading to research into the cardiovascular distribution of MC1R and MC3R in vascular tissue (Van der Ploeg et al., 2002, Proceedings of the National Academy of Sciences). This line of investigation has informed dose-ranging methodology in preclinical study designs.
PT-141 as a Research Tool Compound
In contemporary peptide research, PT-141 is used as a reference compound for melanocortin receptor binding assays, competitive displacement studies, and hypothalamic signaling pathway mapping. Researchers sourcing PT-141 for in vitro or in vivo preclinical use should verify purity via HPLC documentation and confirm identity with mass spectrometry data. Certificate of Analysis (CoA) review is standard practice before use in any assay.
It is important to note that all PT-141 research applications discussed here refer to controlled laboratory and preclinical settings. This compound is not approved for human self-administration and is available strictly for research use only in non-clinical contexts.
Summary
PT-141 (bremelanotide) is a well-characterized melanocortin receptor agonist used in preclinical research to probe MC3R and MC4R pathway biology. Its cyclic structure, central bioavailability, and established SAR foundation make it a valuable tool compound in hypothalamic, behavioral, and receptor pharmacology research. Researchers interested in melanocortin system biology will find PT-141 one of the more thoroughly documented ligands available for in vitro and in vivo model work.
All content on this site is for research and informational purposes only. Core Research Peptides products are not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.
In stock now
Melanotan II 10mg, in stock in the United States
Core Research Peptides stocks Melanotan II 10mg at $39 a vial with published bundle pricing at two, three and five units. Orders placed before 4PM ET dispatch the same day, seven days a week.
Read the Melanotan II buying guideView Melanotan II 10mgFree research guide for this compound at coreresearchpeptides.com/guides.
